Table 2 Primary outcomes and the components of the composite primary outcome

From: Goat lung surfactant for treatment of respiratory distress syndrome among preterm neonates: a multi-site randomized non-inferiority trial

Outcome

GLSE group (n = 52)

Beractant (n = 46)

OR (95% CI)

Risk difference Beractant−GLSE (95% CI)

Death or BPD at 36 weeks PMA

26 (50.0)

18 (39.1)

1.5 (0.7–3.5)

−10.8 (−30.5, 8.7)

Repeat dose of surfactant

34 (65.4)

8 (17.4)

9.0 (3.5–23.3)

−48.0 (−64.9, −31.0)

Death

21 (40.4)

14 (30.4)

1.5 (0.7–3.6)

−9.94 (−28.7, 8.9)

BPD

5/31 (16.1)

4/32 (12.5)

1.6 (0.6–4.9)

−3.6 (−20.9, 13.7)

  1. BPD bronchopulmonary dysplasia, PMA postmenstrual age, OR odds ratio
Back to article page